Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study"
Leuk Res. 2017 Apr:55:55-57.
doi: 10.1016/j.leukres.2017.01.009.
Epub 2017 Jan 9.
1 Department of Haematology, SA Pathology, Adelaide, South Australia, Australia; Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; The University of Adelaide, School of Medicine, Adelaide, South Australia, Australia. Electronic address: amy.hughes@sahmri.com.
2 Department of Haematology, SA Pathology, Adelaide, South Australia, Australia; Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.
3 Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and The University of South Australia, Adelaide, South Australia, Australia; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
4 The University of Adelaide, School of Medicine, Adelaide, South Australia, Australia; Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and The University of South Australia, Adelaide, South Australia, Australia; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
5 Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia.
6 Department of Haematology, SA Pathology, Adelaide, South Australia, Australia; Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; The University of Adelaide, School of Medicine, Adelaide, South Australia, Australia.